about
The oncogenic fusion protein RUNX1-CBFA2T1 supports proliferation and inhibits senescence in t(8;21)-positive leukaemic cellsDevelopment of a preclinical orthotopic xenograft model of ewing sarcoma and other human malignant bone disease using advanced in vivo imagingMAPKAP kinase 2 phosphorylates serum response factor in vitro and in vivoAML1/ETO proteins control POU4F1/BRN3A expression and function in t(8;21) acute myeloid leukemiaAnalysis of the nuclear distribution of the translocation t(8;21)-derived fusion protein AML1/ETO by confocal laser scanning microscopy.Evaluation of the effectiveness of DNA-binding drugs to inhibit transcription using the c-fos serum response element as a target.The MLL recombinome of acute leukemias in 2013.Determination of key structure-activity relationships in siRNA delivery with a mixed micelle system.Oncogene suppression by small interfering RNAs.RNA interference as a potential tool in the treatment of leukaemia.Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding.UBASH3B/Sts-1-CBL axis regulates myeloid proliferation in human preleukemia induced by AML1-ETO.Understanding the cancer stem cell.siRNA-mediated AML1/MTG8 depletion affects differentiation and proliferation-associated gene expression in t(8;21)-positive cell lines and primary AML blasts.The MLL recombinome of acute leukemias in 2017.Lineage-inappropriate PAX5 expression in t(8;21) acute myeloid leukemia requires signaling-mediated abrogation of polycomb repression.Molecular parameters of siRNA--cell penetrating peptide nanocomplexes for efficient cellular delivery.RNase H-independent antisense activity of oligonucleotide N3 '--> P5 ' phosphoramidates.Inhibition of adhesion molecule expression on human venous endothelial cells by non-viral siRNA transfection.Targeting MLL-AF4 with short interfering RNAs inhibits clonogenicity and engraftment of t(4;11)-positive human leukemic cells.Specific inhibition of bcr-abl gene expression by small interfering RNA.Detection and quantification of CBFB/MYH11 fusion transcripts in patients with inv(16)-positive acute myeloblastic leukemia by real-time RT-PCR.BCP-ALL blasts are not dependent on CD19 expression for leukaemic maintenance.Long-term in vitro maintenance of clonal abundance and leukaemia-initiating potential in acute lymphoblastic leukaemia.Lentiviral marking of patient-derived acute lymphoblastic leukaemic cells allows in vivo tracking of disease progression.Cleavage of AML1/MTG8 by asymmetric hammerhead ribozymes.Serum response factor is crucial for actin cytoskeletal organization and focal adhesion assembly in embryonic stem cells.Abundant and equipotent founder cells establish and maintain acute lymphoblastic leukaemia.AML1/MTG8 oncogene suppression by small interfering RNAs supports myeloid differentiation of t(8;21)-positive leukemic cells.Proliferation of human primary vascular smooth muscle cells depends on serum response factor.New insights to the MLL recombinome of acute leukemias.Malignant stem cells in childhood ALL: the debate continues!Targeting oncogenes with siRNAs.Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia.Leukemic fusion genes MLL/AF4 and AML1/MTG8 support leukemic self-renewal by controlling expression of the telomerase subunit TERT.Transient depletion of RUNX1/RUNX1T1 by RNA interference delays tumour formation in vivoA novel translocation, t(14;19)(q32;p13), involving IGH@ and the cytokine receptor for erythropoietinReal-time RT-PCR for the detection and quantification of AML1/MTG8 fusion transcripts in t(8;21)-positive AML patientsAML1/ETO inhibits AML1/CCAAT-enhancer binding protein-alpha mediated activation of the CD11c promoter and represses CD11c expression in HL60 cellsGene silencing by RNAi in mammalian cells
P50
Q24800256-658C40C0-75E3-41A3-BF4A-44505F625B53Q28538391-7508E7F2-6C77-4E40-BE94-04DD927E2252Q28609315-88706CDF-248C-43A8-BDA6-F3A4B138483EQ28751687-28C6F01A-6430-4A81-BC12-CDFCEB8BB046Q30834801-7521A134-A690-4656-89C6-1E9C31944D26Q33181165-43C98AF6-F51B-430D-8FC8-392946F50B4DQ34651113-F3123E1B-8F84-40DE-B4DE-A4C3FDD453ECQ35021068-88842F45-53C4-4F74-AAFB-331A65E42A92Q35867278-DF1E8546-B72D-4D0D-8C3F-E760FFF8D00EQ35967287-6FED1FCE-9020-46A5-8439-FED6F4E5636CQ36166902-F3C421E6-5581-4369-A9A9-CC962518B732Q36642902-764E497A-C65B-4AD0-A6FC-7D09990AFA0BQ37776152-8C67E208-7A3E-420A-9491-A743E2C24140Q38313725-317F6BF1-92E8-412D-BABA-4AD9C0911686Q38681972-EA56DA06-C09D-4A1E-A04A-D474E7B7C3CBQ39160809-55DE76A7-2A2D-40D8-B343-D08A2366D965Q39163813-5A738BB7-0995-47D2-B453-006D43AE260CQ39719200-748157A9-A61F-4301-8AB3-52EDA37558B4Q39739512-19FED153-4C0C-4952-B60E-DB8DE8816D6CQ40392839-D2A56E5F-93C0-4EE6-B608-2C87AB5AAA9EQ40695166-B5CD353B-60A9-4B1E-8734-9DFDC7B47D04Q40821721-1E7EEFE0-57FD-419D-9651-3BF43CFFF69FQ41979757-CD78918C-F390-4210-A8A2-EB16E75EF95DQ42041565-8BB52DD4-5FB0-4A85-BADD-33813832389AQ42149153-1942EBF3-F85F-4E1D-ABE9-95ABD9CE6388Q42653016-6B36326B-927F-4117-970C-BF1B5F80DF89Q42918539-72AB24E2-A925-4B44-9ED9-8D17CD05B07EQ43072196-047F489F-F0FB-499E-AF11-2EEF12B3BB22Q44248072-2802D070-9ED4-43F8-A79F-C63934B581C4Q44284667-3B79B332-1686-4267-8F18-4A5C6A526CF9Q44945193-BBEFC2C8-055F-4C9A-8B25-9DFC016FAC55Q47906003-0106A073-BC57-4D47-8F85-83E96AB393E2Q51757691-67DAAF5E-2C3A-4D79-9A10-8788C326E4F9Q53307880-AAEE5011-9CDD-4BB8-BD63-B75EB2CEAB26Q54416763-B5E89FF0-D420-44FC-83A7-E88182189EE2Q57201674-D80DEE8F-7A09-4BCA-8FBE-4F97011B3DD3Q58481827-F0F61BF0-A553-43EF-8F45-0443153CBDC3Q73079896-50346282-F1B9-4E5A-A100-0080C772AC8BQ73847999-9E4779BF-ECB8-45D8-AFFA-F1E7A5871653Q80674077-94336CF3-A089-4F2F-81CC-CC68BB056935
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Olaf Heidenreich
@ast
Olaf Heidenreich
@en
Olaf Heidenreich
@es
Olaf Heidenreich
@nl
Olaf Heidenreich
@sl
type
label
Olaf Heidenreich
@ast
Olaf Heidenreich
@en
Olaf Heidenreich
@es
Olaf Heidenreich
@nl
Olaf Heidenreich
@sl
prefLabel
Olaf Heidenreich
@ast
Olaf Heidenreich
@en
Olaf Heidenreich
@es
Olaf Heidenreich
@nl
Olaf Heidenreich
@sl
P106
P1153
7005213313
P21
P31
P496
0000-0001-5404-6483